Dr. Hayes Discusses Tumor Biomarker Tests in Breast Cancer

Daniel F. Hayes, MD
Published: Friday, Mar 17, 2017



Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.

In the adjuvant setting, tumor biomarkers can provide an indication of the present of future behavior of a cancer. Multiple tests exist to measure these biomarkers, but the question among clinicians is: which test should be ordered?

In the adjuvant setting, 3 tumor biomarker tests—Prosigna, EndoPredict and Breast Cancer Index—have shown significant clinical utility, says Hayes. These multi-parameter assays measure either transcript or protein expression and have demonstrated analytic validity for prognosis in patients with ER-positive/HER2-negative, node-negative breast cancer.

<<< View more from the St. Gallen's Breast Cancer Conference


Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.

In the adjuvant setting, tumor biomarkers can provide an indication of the present of future behavior of a cancer. Multiple tests exist to measure these biomarkers, but the question among clinicians is: which test should be ordered?

In the adjuvant setting, 3 tumor biomarker tests—Prosigna, EndoPredict and Breast Cancer Index—have shown significant clinical utility, says Hayes. These multi-parameter assays measure either transcript or protein expression and have demonstrated analytic validity for prognosis in patients with ER-positive/HER2-negative, node-negative breast cancer.

<<< View more from the St. Gallen's Breast Cancer Conference

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x